natgillin/translations-raw huggingface dataset:
This medicine is not recommended for patients with severely reduced liver function due to the lack of data in these patients.
Zaradi pomanjkanja podatkov uporaba zdravila Vipidia pri bolnikih s hudo okvaro delovanja jeter ni priporočljiva.
This medicine is not recommended for use in children and adolescents under 18 years.
Tega zdravila ni priporočljivo uporabljati pri otrocih in mladostnikih, mlajših od 18 let.
This medicine is not recommended for use in children and adolescents under 18 years.
To zdravilo ni priporočeno za zdravljenje otrok in mladostnikov, mlajših od 18 let.
This medicine is not recommended for use in patients under the age of 3 years.
To zdravilo ni priporočljivo za uporabo pri bolnikih, mlajših od 3 let.
This medicine is not recommended for use in patients under the age of 3 years.
To zdravilo ni priporočljivo za uporabo pri otrocih, mlajših kot 3 leta.
This medicine is not recommended if you have a severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or inflammatory bowel disease.
Uporaba zdravila ni priporočena, če imate hude težave z želodcem ali črevesjem in se vam zato želodec počasneje prazni (gastropareza) ali če imate kronično vnetno črevesno bolezen.
This medicine is not recommended if you have severe kidney problems; if you have liver problems.
Zdravila Topotekan Eagle se ne priporoča v primeru hudih težav z ledvicami; če imate težave z jetri.
This medicine is not recommended if you have severe kidney problems; if you have liver problems.
Zdravilo Topotekan Eagle se ne priporoča v primeru hudih težav z ledvicami; če imate težave z jetri.
This medicine is not recommended if you have severe liver problems; if you have lung problems, or if you have had lung problems before from using other medicines or radiation.
Zdravila Topotekan Eagle se ne priporoča v primeru hudih težav z jetri; če imate težave s pljuči ali ste že imeli težave s pljuči zaradi drugih zdravil ali obsevanja.
This medicine is not recommended if you have severe liver problems; if you have lung problems, or if you have had lung problems before from using other medicines or radiation.
Zdravilo Topotekan Eagle se ne priporoča v primeru hudih težav z jetri; če imate težave s pljuči ali če ste že imeli težave s pljuči zaradi drugih zdravil ali obsevanja.
This medicine is not recommended if you have severely reduced liver function.
To zdravilo se ne priporoča, če imate hudo zmanjšano delovanje jeter.
This medicine is not recommended in children under the age of 12 years for the treatment of asthma, or in children and adolescents of any age for the treatment of COPD.
Tega zdravila ne smete dajati za zdravljenje astme otrokom, mlajšim od 12 let, ali za zdravljenje KOPB otrokom in mladostnikom ne glede na starost.
This medicine is only for injection just under the skin of your belly (subcutaneous).
To zdravilo je namenjeno samo dajanju v obliki injekcije tik pod kožo v trebuh (subkutano).
This medicine is only for you – do not let anyone else use it.
To zdravilo je le za vas - ne dovolite, da bi ga uporabil kdo drug.
This medicine is only intended for use in post- menopausal women.
To zdravilo je namenjeno samo ženskam po menopavzi.
This medicine is prescribed to you because you have anaemia caused by your chronic kidney disease and associated whith typical symptoms, such as tiredness, weakness and shortness of breath.
Zdravilo so vam predpisali, ker imate anemijo, ki jo je povzročila kronična bolezen vaših ledvic in je povezana s tipičnimi simptomi, kot so utrujenost, oslabelost in pojemanje sape.
This medicine is presented as light brown gastro-resistant granules in sachets.
Zdravilo je v obliki svetlorjavih gastrorezistentnih zrnc v vrečkah.
This medicine is related to thalidomide and belongs to a group of medicines which affect the immune system (the body’s natural defences).
To zdravilo je sorodno talidomidu in spada v skupino zdravil, ki vplivajo na delovanje imunskega sistema (naravna obramba telesa).
This medicine is subject to additional monitoring.
<Za to zdravilo se izvaja dodatno spremljanje varnosti.
This medicine is subject to additional monitoring.
Za to cepivo se izvaja dodatno spremljanje varnosti.
This medicine is subject to restricted medical prescription by your doctor.
Predpisovanje in izdaja zdravila je le s posebnim režimom.
This medicine is taken by mouth for diabetes.
To je zdravilo za zdravljenje sladkorne bolezni, ki ga je treba zaužiti.
This medicine is taken in combination with diet and exercise.
To zdravilo morate jemati v kombinaciji z dieto in telesno dejavnostjo.
This medicine is the same as Arava, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Arava, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Betaferon, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Betaferon, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Forxiga, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Forxiga, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Previcox oral paste for horses, which is already authorised in the European Union.
To zdravilo je enako zdravilu Previcox, peroralna pasta za konje, ki je v Evropski uniji že odobreno.
This medicine is the same as Procoralan, which is already authorised in the EU.
To zdravilo je enako zdravilu Procoralan, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Relvar Ellipta, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Relvar Ellipta, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Renvela, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Renvela, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Tracleer, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Tracleer, ki je že odobreno v Evropski uniji (EU).
This medicine is the same as Xigduo, which is already authorised in the European Union (EU).
To zdravilo je enako zdravilu Xigduo, ki je že odobreno v Evropski uniji (EU).
This medicine is unlikely to affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo Relvar Ellipta vplivalo na sposobnost upravljanja vozil in strojev.
This medicine is unlikely to affect your ability to drive or use machines.
Ni verjetno, da bi zdravilo Revinty Ellipta vplivalo na sposobnost upravljanja vozil in strojev.
This medicine is used if your diabetes cannot be controlled with other medicines used to treat diabetes, along with diet and exercise.
To zdravilo se uporablja, če sladkorne bolezni ni mogoče urediti z drugimi zdravili za zdravljenje sladkorne bolezni, skupaj z dieto in s telesno dejavnostjo.
This medicine is used if your diabetes cannot be controlled with other oral diabetes medicines, along with diet and exercise.
To zdravilo uporabljamo, če sladkorne bolezni ni mogoče obvladati z drugimi peroralnimi zdravili za sladkorno bolezen, hkrati z dieto in telesno dejavnostjo.
This medicine is used in combination with another cancer medicine (docetaxel) to treat a cancer of the lung called non-small cell lung cancer (NSCLC).
To zdravilo se uporablja v kombinaciji z drugim zdravilom za zdravljenje raka (docetaksel), ki se uporablja za zdravljenje vrste pljučnega raka imenovanega nedrobnocelični pljučni rak (non-small cell lung cancer – NSCLC).
This medicine is used in combination with the following diabetes medicines: metformin, sulphonylureas and thiazolidinediones.
To zdravilo uporabljamo v kombinaciji z naslednjimi zdravili za sladkorno bolezen: metformin, sulfonilsečnine in tiazolidindioni.
This medicine is used in patients who have ‘congenital antithrombin deficiency’ (inherited low levels of the protein antithrombin).
To zdravilo se uporablja pri bolnikih, ki imajo »prirojeno pomanjkanje antitrombina« (podedovane nizke ravni beljakovine antitrombin).
This medicine is used on its own to treat adult patients with a specific type of cancer of the lung (non-small cell lung cancer): that is identified by a change (mutation) in the gene for EGFR.
To zdravilo se uporablja samostojno za zdravljenje odraslih bolnikov s posebno obliko pljučnega raka (nedrobnoceličnega pljučnega raka): s spremembo (mutacijo) gena EGFR.
This medicine is used to make breathing easier for adult patients who have breathing difficulties due to a lung disease called chronic obstructive pulmonary disease (COPD).
To zdravilo uporabljamo za lajšanje dihanja pri odraslih bolnikih, ki imajo težave z dihanjem zaradi bolezni, ki se imenuje kronična obstruktivna pljučna bolezen (KOPB).
This medicine is used to treat a type of diabetes called ‘type 2 diabetes’.
To zdravilo uporabljamo za zdravljenje vrste sladkorne bolezni, imenovane "sladkorna bolezen tipa 2".
This medicine is used to treat adults with a lack (deficiency) of growth hormone who
To zdravilo se uporablja za odrasle s pomanjkanjem rastnega hormona, ki
This medicine is used to treat chronic myeloid leukaemia (CML) in adults.
Zdravilo uporabljamo za zdravljenje kronične mieloične levkemije (KML) pri odraslih.
This medicine is used to treat chronic spontaneous urticaria in adults and adolescents (12 years of age or older) who are already receiving antihistamines but whose CSU symptoms are not well controlled by these medicines.
To zdravilo se uporablja za zdravljenje kronične spontane urtikarije pri odraslih in mladostnikih (starih 12 let ali več), ki že prejemajo antihistaminike, vendar njihovi simptomi kronične spontane urtikarije s temi zdravili niso dobro urejeni.
This medicine is used to treat Generalised Anxiety Disorder (GAD).
To zdravilose uporablja za zdravljenje generalizirane anksiozne motnje (GAD – Generalised Anxiety Disorder).
This medicine is used to treat ‘attention deficit hyperactivity disorder’ (ADHD) in children and adolescents 6-17 years old for whom current stimulant medication is not appropriate and/or current medication does not adequately control ADHD symptoms.
To zdravilo uporabljamo za zdravljenje ‘motnje pozornosti s hiperaktivnostjo’ (ADHD- attention deficit hyperactivity disorder) pri otrocih in mladostnikih, starih 6-17 let, za katere trenutna spodbujevalna zdravila niso primerna in/ali trenutna zdravila simptomov ADHD ne obvladujejo ustrezno.
This medicine is usually given by injection underneath the skin (subcutaneous).
To zdravilo se običajno vbrizgava pod kožo (subkutano).
This medicine is usually given every day.
To zdravilo se običajno daje vsak dan.
This medicine itself has no influence on the ability to drive and use machines.
To zdravilo ne vpliva na sposobnost vožnje in upravljanja s stroji.
This medicine may affect your blood pressure, so it should be measured regularly, especially at the beginning of your treatment.
To zdravilo lahko vpliva na vaš krvni tlak, zato ga morate redno meriti, zlasti na začetku zdravljenja.
This medicine may also cause flu-like symptoms (including tiredness, nausea, fever, muscle and joint pain, and shivering) before or during the occurrence of local skin reactions.
To zdravilo lahko pred pojavom lokalnih kožnih reakcij ali med njim povzroči tudi gripi podobne simptome (vključno z utrujenostjo, navzeo, zvišano telesno temperaturo, bolečinami v mišicah in sklepih in mrazenjem).
This medicine may also stop some other medicines from working as well, e.g. levodopa (used to treat Parkinson’s disease).
To zdravilo lahko tudi prepreči delovanje nekaterih drugih zdravil, npr. levodope (ki se uporablja za zdravljenje Parkinsonove bolezni).
This medicine may be removed from the refrigerator for a maximum period of 24 hours at room temperature (up to 25C).
To zdravilo se lahko vzame iz hladilnika za največ 24 ur pri sobni temperaturi (do 25 C).
This medicine may be taken with or without food.
To zdravilolahko jemljete s hrano ali brez nje.
This medicine may be used while your partner is breast-feeding.
Zdravilo lahko uporabljate, medtem ko vaša partnerka doji.
This medicine may cause an electrocardiogram (ECG) abnormality demonstrating a long time for an electrical impulse to travel through a certain part of the heart (known as “QT prolongation”).
To zdravilo lahko povzroči abnormalnost na elektrokardiogramu (EKG), ki se kaže kot podaljšano potovanje impulza skozi določen del srca (imenovano tudi »podaljšanje intervala QT«).
This medicine may cause bleeding, especially tumour-related bleeding.
to zdravilo lahko povzroči krvavitve, posebno krvavitve, povezane s tumorjem.
This medicine may cause blurring or loss of vision, or other changes in eyesight, many of which are temporary.
Uporabatega zdravila lahko povzroči zamegljenost ali izgubo vida ali druge spremembe vida, med katerimi so mnoge začasne.
This medicine may cause fever (see also section 4).
To zdravilo lahko povzroči zvišano telesno temperaturo (glejte tudi poglavje 4).
This medicine may cause harm to the unborn child if it is taken by women who are pregnant.
Zdravilo lahko škoduje otroku, če ga jemlje noseča ženska.
This medicine may cause harm to the unborn child if it is taken by women who are pregnant.
Če nosečnica vzame to zdravilo, lahko to škoduje nerojenemu otroku.
This medicine may cause harm to your unborn child if taken during pregnancy. if you have any unexplained vaginal bleeding.
Če bi to zdravilo jemali v nosečnosti, bi lahko škodovalo vašemu nerojenemu otroku. če imate nepojasnjeno krvavitev iz nožnice.
This medicine may cause infections and a decreased number of your neutrophils (a type of blood cell important for your protection against bacteria).
to zdravilo lahko povzroči okužbe in zmanjša število vaših nevtrofilcev (vrsta krvnih celic, ki so pomembne za zaščito pred bakterijami);
This medicine may cause some drowsiness.
To zdravilo lahko povzroča zaspanost.
This medicine may cause unexpected vaginal bleeding or spotting during the weeks when you are wearing the patch.
V tednih, ko uporabljate to zdravilo lahko pride do vmesnih krvavitev ali kapljičnih krvavitev.
This medicine may contain a trace of lecithin which is derived from soya.
To zdravilo lahko vsebuje sledove lecitina iz soje.
This medicine may harm your unborn baby since it may stop new blood vessels from forming.
To zdravilo namreč lahko škoduje nerojenemu otroku – prepreči lahko nastajanje novih žil.
This medicine may have a minor influence on your ability to drive or use tools or machines.
To zdravilo ima blag vpliv na sposobnost upravljanja vozil in strojev.
This medicine may have a moderate effect on your ability to drive or use any tools or machines as the side effects for Xtandi include seizures.
To zdravilo ima lahko zmeren vpliv na vašo sposobnost upravljanja vozil in uporabo orodij ali strojev, ker neželeni učinki zdravila Xtandi vključujejo napade krčev.
This medicine may have minor influence on your ability to drive and use machines.
To zdravilo ima lahko blag vpliv na sposobnost upravljanja vozil in strojev.
This medicine may increase your risk of developing OHSS.
To zdravilo lahko poveča tveganje za razvoj OHSS.
This medicine may make you feel dizzy and drowsy.
To zdravilo lahko povzroča omotičnost in zaspanost.
This medicine may make you feel dizzy, drowsy, nauseous or have a headache.
Zaradi tega zdravila lahko postanete omotični oziroma zaspani, lahko vam postane slabo ali vas boli glava.
This medicine may make you feel dizzy.
To zdravilo lahko povzroča omotičnost.
This medicine may make you feel dizzy.
To zdravilo lahko povzroči omotico.
This medicine may make your child feel sleepy.
Zaradi tega zdravila lahko postane vaš otrok zaspan.
This medicine may mask pain symptoms that could assist in the diagnosis of some diseases.
To zdravilo lahko zakrije simptome bolečine, ki lahko pomagajo pri diagnozi nekaterih bolezni.
This medicine may pose a risk to the environment.
Zdravilo lahko predstavlja nevarnost za okolje.
This medicine may reduce your appetite, the amount of food you eat, and your weight.
To zdravilo Byetta lahko zmanjša vaš apetit, količino zaužite hrane in vašo telesno maso.
This medicine might make some people feel dizzy or affect their vision or hearing.
To zdravilo lahko pri nekaterih ljudeh povzroči omotico in vpliva na vid ali sluh.
This medicine might make some people feel dizzy or affect their vision or hearing.
Zdravilo Sildenafil ratiopharm lahko pri nekaterih ljudeh povzroči omotico in vpliva na vid ali sluh.
This medicine must be dissolved before use.
Pred uporabo je treba to zdravilo raztopiti.
This medicine must be kept out of the sight and reach of children.
To zdravilo shranjujte nedosegljivo otrokom
This medicine must be used within 28 days of first opening the bottle.
To zdravilo morate porabiti v 28 dneh po odprtju steklenice.
This medicine must not be administered by the intramuscular route.
Tega zdravila ne smete injicirati v mišico.
This medicine must not be taken with food (see section 3, “Taking this medicine”).
Zdravila ne smete jemati skupaj s hrano (glejte poglavje 3, “Jemanje zdravila”).
This medicine must only be used by parents/carers where the child has been diagnosed to have epilepsy.
Zdravilo BUCCOLAM lahko uporabljajo le starši/skrbniki pri bolnikih z diagnozo epilepsije.
This medicine should be taken once a day either in the morning or evening.
To zdravilo je treba jemati enkrat na dan, bodisi zjutraj bodisi zvečer.
This medicine should be taken with a meal or light snack.
Zdravilo morate vzeti ob obroku ali z lahkim prigrizkom.
This medicine should be used only in case of administration of 20 mg three times a day.
To zdravilo se lahko uporablja samo za odmerjanje 20 mg trikrat na dan.
This medicine should not affect your ability to drive or use machines.
To zdravilo ne vpliva na sposobnost upravljanja vozil in strojev.
This medicine should not be given to children and adolescents between the ages of 0 and under 18 years because it has not been tested in this age group.
To zdravilo se ne sme uporabljati pri otrocih in mladostnikih, starih od 0 do 18 let, saj se pri tej starostni skupini ni proučevalo.
This medicine should NOT be given to children and adolescents under the age of 18.
Otroci in mladostniki do 18. leta starosti NE smejo dobiti tega zdravila.
This medicine should not be given to children or adolescents below the age of 18 years.
Tega zdravila ne smejo dobiti otroci ali mladostniki, mlajši od 18 let.
This medicine should not be given to children or adolescents below the age of 18 years.
Zdravila ne smejo dobiti otroci in mladostniki, mlajši od 18 let.
This medicine should not be given to patients whose body breaks down this medicine at very fast speed (known as ‘ultrarapid metabolisers’) or to those for whom the ability to break down the medicine is unknown or for whom no test has been done.
Zdravilo se ne sme dajati bolnikom, pri katerih razgradnja tega zdravila poteka zelo hitro (imenujemo jih „ultra hitri presnavljalci“), ali tistim, pri katerih sposobnost razgradnje zdravila ni znana oziroma pri katerih ni bil opravljen ustrezen test.
This medicine should not be mixed with any other injections or infusions.
Tega zdravila ne smete mešati z drugimi injekcijami ali infuzijami.
This medicine should not be used after the expiry date shown on the carton, blister pack and vials.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je označen na škatli, pretisnem omotu in vialah..
This medicine should not be used by children and adolescents under 18 years of age.
Tega zdravila ne smejo jemati otroci in mladostniki, mlajši od 18 let.
This medicine should not be used during pregnancy and breastfeeding unless clearly necessary.
Tega zdravila se ne sme uporabljati med nosečnostjo in obdobjem dojenja, razen če je izrecno potrebno.
This medicine should not be used for the treatment of asthma.
Tega zdravila ne smete uporabljati za zdravljenje astme,
This medicine should not be used for treatment of patients with constipation which is not related to opioid use.
Tega zdravila se ne sme uporabljati za zdravljenje bolnikov s konstipacijo, ki ni povezana z uporabo opioidov.
This medicine should not be used in children or adolescents under 18 year of age.
Zdravila ni dovoljeno uporabljati pri osebah, mlajših od 18 let, niso izvedli.
This medicine should not be used in children or adolescents under 18 years of age.
To zdravilo ne smejo uporabljati otroci in mladostniki, mlajši od 18 let.
This medicine should not be used in children under 6 years of age and adults 18 years and over because it is not known if it works or is safe.
Pri otrocih, mlajših od 6 let, in odraslih, starih 18 let ali več, se to zdravilo ne sme uporabljati, ker ni znano, ali deluje in ali je varno.
This medicine should not be used to treat this condition;
Tega zdravila se ne sme uporabljati za zdravljenje te bolezni.
This medicine stimulates your body’s own immune system to produce natural substances which help fight your actinic keratosis.
To zdravilo spodbuja vaš imunski sistem da proizvaja naravne snovi, ki pomagajo v boju proti aktinični keratozi.
This medicine will be given by your doctor or nurse.
To zdravilo vam bosta odmerjala zdravnik ali medicinska sestra.
This medicine will be given to you under medical supervision, it is therefore unlikely that you will be given too much.
To zdravilo boste prejeli pod zdravniškim nadzorom in je zato malo verjetno, da ga boste prejeli preveč.
This medicine will be given to you under medical supervision; it is, therefore, unlikely that you will be given too much.
To zdravilo boste prejemali pod zdravniškim nadzorom, zato je malo verjetno, da boste prejeli prevelik odmerek.
This medicine will be given to you under medical supervision; it is, therefore, unlikely that you will be given too much.
Zdravilo boste prejemali pod zdravniškim nadzorom, zato je malo verjetno, da boste prejeli prevelik odmerek.
This medicine will not affect your ability to drive or use machines but take care if you experience abnormal vision.
To zdravilo ne vpliva na sposobnost upravljanja vozil strojev, vendar pa bodite pozorni v primeru pojava težav z vidom.
This medicine works by neutralising the activity of a protein called IL-17A, which promotes psoriasis.
To zdravilo deluje tako, da nevtralizira aktivnost beljakovine, imenovane IL-17A, ki pripomore k nastanku psoriaze.
This medicine works in two ways.
Zdravilo deluje na dva načina.
This medicine works on areas on the brain involved in the control of food intake and energy expenditure.
To zdravilo učinkuje na predele v možganih, vključene v nadzor vnosa hrane in porabe energije.
This medicine, when given with ribavirin capsules, is usually given at a dose of 1.5 microgram per kilogram of body weight once a week.
Kadar uporabljate to zdravilo skupaj s kapsulami ribavirina, je odmerek običajno 1,5 mikrograma na kilogram telesne mase enkrat na teden.
This medicinedoes not require any special storage conditions.
Za shranjevanje ni posebnih navodil.
This messenger is involved in causing inflammation and is found at high levels in patients with rheumatoid arthritis, systemic juvenile idiopathic arthritis and juvenile idiopathic polyarthritis.
Ta sporočilna molekula sodeluje pri povzročanju vnetja in je pri bolnikih z revmatoidnim artritisom, aktivnim sistemskim juvenilnim idiopatskim artritisom ali juvenilnim idiopatskim poliartritisom prisotna v visokih ravneh.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Cimzia is used to treat.
Ta prenašalec sodeluje pri povzročanju vnetja in je pri bolnikih z boleznimi, ki se zdravijo z zdravilom Cimzia, prisoten v visokih koncentracijah.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Humira is used to treat.
Ta prenašalec sodeluje pri vnetjih in je prisoten v visokih koncentracijah pri bolnikih z boleznimi, za katere se zdravilo Humira uporablja.
This messenger is involved in causing inflammation and is found at high levels in patients with the diseases that Remsima is used to treat.
Ta prenašalec sodeluje pri povzročanju vnetja in ga je pri bolnikih z boleznimi, za zdravljenje katerih se uporablja zdravilo Remsima, mogoče najti v velikih koncentracijah.